Following comments received in the draft scope consultation NICE decided to split this Multiple Technology Appraisal (MTA) of three drugs into three separate Single Technology Appraisals (STAs). The STAs are:
[ID1478] – dapagliflozin
(https://www.nice.org.uk/guidance/indevelopment/gid-ta10374)
[ID1376] – sotagliflozin
(https://www.nice.org.uk/guidance/indevelopment/gid-ta10376)
[ID1275] – empagliflozin
(https://www.nice.org.uk/guidance/indevelopment/gid-ta10375).
This MTA is therefore suspended.
| Status | Discontinued |
| Decision | Selected |
| Process | TA |
| ID number | 1217 |
Project Team
| Project lead | Jeremy Powell |
Email enquiries
- If you have any queries please email TACommB@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 12 June 2018 | Discontinued. Following comments received in the draft scope consultation NICE decided to split this Multiple Technology Appraisal (MTA) of three drugs into three separate Single Technology Appraisals (STAs). The STAs are: [ID1478] – dapagliflozin (https://www.nice.org.uk/guidance/indevelopment/gid-ta10374) [ID1376] – sotagliflozin (https://www.nice.org.uk/guidance/indevelopment/gid-ta10376) [ID1275] – empagliflozin (https://www.nice.org.uk/guidance/indevelopment/gid-ta10375). This MTA is therefore suspended. |
| 15 March 2018 | In progress. Topic referred 13 February 2018 |
| 07 November 2017 (00:00) | Scoping workshop |
| 19 September 2017 - 17 October 2017 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual